business
DexCom, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All
Key takeaways
- (DXCM) Further Advances Vision of Glucose Biosensing for All Fatima Gulzar Mon, June 29, 2026 at 2:58 AM GMT+7 1 min read DXCM Dex Com, Inc.
- (NASDAQ:DXCM) announced that the FDA cleared growing use of its Stelo Glucose Biosensor beyond adults for children ages 2 and older who do not use insulin.
- President and CEO Jake Leach said, "Glucose matters for everyone." The company plans to broaden access to glucose biosensing while making preventive, customized care more accessible through a redesigned Stelo app.
Dex Com, Inc. (DXCM) Further Advances Vision of Glucose Biosensing for All Fatima Gulzar Mon, June 29, 2026 at 2:58 AM GMT+7 1 min read DXCM Dex Com, Inc. (NASDAQ:DXCM) is among the Best Healthcare Stocks.
On June 23, Dex Com, Inc. (NASDAQ:DXCM) announced that the FDA cleared growing use of its Stelo Glucose Biosensor beyond adults for children ages 2 and older who do not use insulin.
President and CEO Jake Leach said, "Glucose matters for everyone." The company plans to broaden access to glucose biosensing while making preventive, customized care more accessible through a redesigned Stelo app.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop